Chronic renal allograft damage after transplantation: What are the reasons, what can we do?

Current Opinion in Organ Transplantation

Volumn 17, Issue 6, 2012, Pages 634-639

  Renders, Lutz ^a   Heemann, Uwe ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

chronic rejection; chronic renal allograft damage; intestitial fibrosis tubular atrophy; therapy

Indexed keywords

ALLOANTIGEN; ANGIOTENSIN 1 RECEPTOR; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; DOPAMINE; FICOLIN; KIDNEY INJURY MOLECULE 1; LEUKOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MANNOSE BINDING LECTIN 2; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PRASTERONE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT REJECTION; APOPTOSIS; ARTERY INTIMA PROLIFERATION; CADAVER; CHRONIC GRAFT REJECTION; CHRONIC RENAL ALLOGRAFT DAMAGE; COLD ISCHEMIA; EXPLANT; GENETIC POLYMORPHISM; GRAFT SURVIVAL; HUMAN; INNATE IMMUNITY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PROTEINURIA; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ACUTE-PHASE PROTEINS; COLD ISCHEMIA; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; ISOANTIGENS; KIDNEY; KIDNEY TRANSPLANTATION; LECTINS; LIPOCALINS; MANNOSE-BINDING LECTIN; MEMBRANE GLYCOPROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84870255948     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835a4bfa     Document Type: Review

References (84)

1. Harlan WR Jr, Holden KR, Williams GM, Hume DM. Proteinuria and nephrotic syndrome associated with chronic rejection of kidney transplants. N Engl J Med 1967; 277:769-776.
2. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-760. (Pubitemid 351347767)
3. Hoy WE, Douglas-Denton RN, Hughson MD, et al. A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney Int Suppl 2003; 83:S31-S37. (Pubitemid 36126840)
4. Tullius SG, Heemann U, Hancock WW, et al. Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg 1994; 220:425-432; discussion 32-35.
5. Delanaye P, Weekers L, Dubois BE, et al. Outcome of the living kidney donor. Nephrol, Dial, Transplant 2012; 27:41-50.
6. Balachandran VP, Aull MJ, Charlton M, et al. Kidneys from older living donors provide excellent intermediate-term outcomes after transplantation. Transplantation 2012; 94:499-505.
7. Friman S, Norden G, Lennerling A, et al. Kidney transplantation: a 46-year experience from the Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden. Clin Transpl 2011; 2011:119-125.
8. Najafian B, Kasiske BL. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2008; 17:149-155. (Pubitemid 351253039)
9. Pratschke J, Wilhelm MJ, Laskowski I, et al. Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 2001; 12:2474-2481. (Pubitemid 33021126)
10. lznerowicz A, Chudoba P, Kaminska D, et al. Duration of brain death and cold ischemia time, but not warm ischemia time, increases expression of genes associated with apoptosis in transplanted kidneys from deceased donors. Transplant Proc 2011; 43:2887-2890.
11. Kunzendorf U, Hohenstein B, Oberbarnscheid M, et al. Durationofdonor brain death and its influence on kidney graft function. Am J Transplant 2002; 2:292-294. (Pubitemid 36330249)
12. Szabo A, Heemann U. Ischemia reperfusion injury and chronic allograft rejection. Transplant Proc 1998; 30:4281-4284. (Pubitemid 29013225)
13. Kaminska D, Koscielska-Kasprzak K, Drulis-Fajdasz D, et al. Kidney ischemic injury genes expressed after donor brain death are predictive for the outcome of kidney transplantation. Transplant Proc 2011; 43:2891-2894.
14. Korbely R, Wilflingseder J, Perco P, et al. Molecular biomarker candidates of acute kidney injury in zero-hour renal transplant needle biopsies. Transpl Int 2011; 24:143-149.
15. Andrade-Oliveira V, Campos EF, Goncalves-Primo A, et al. TLR4 mRNA levels as tools to estimate risk for early posttransplantation kidney graft dysfunction. Transplantation 2012; 94:589-595.
16. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc 1956; 160:277-282.
17. Tilney NL. Renal transplantation between identical twins: a review. World J Surg 1986; 10:381-388.
18. Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982; 34:347-351. (Pubitemid 13170993)
19. Kessaris N, Mukherjee D, Chandak P, Mamode N. Renal transplantation in identical twins in United States and United Kingdom. Transplantation 2008; 86:1572-1577.
20. Ravindranath MH, Pham T, Ozawa M, Terasaki PI. Antibodies to HLA-E may account for the nondonor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients. Int Immunol 2012; 24:43-57.
21. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
22. Dragun D, Catar R, Kusch A, et al. Non-HLA-antibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Human Immunol 2012. [Epub ahead of print]
23. Dragun D, Philippe A, Catar R. Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant 2012; 17:440-445.
24. Eikmans M, de Canck I, van der Pol P, et al. The functional polymorphism Ala258Ser in the innate receptor gene Ficolin-2 in the donor predicts improved renal transplant outcome. Transplantation 2012; 94:478-485.
25. Eurich D, Boas-Knoop S, Yahyazadeh A, et al. Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease. Transplant Infect Dis 2012; 14:488-495.
26. Eurich D, Boas-Knoop S, Bahra M, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93:644-649.
27. Tullius SG, Heemann UW, Azuma H, et al. Alloantigen-independent factors lead to signs of chronic rejection in long-term kidney isografts. Transplant Int 1994; 7 (Suppl 1):S306-S307.
28. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344:1737-1738.
29. Muller V, Becker G, Delfs M, et al. Do urinary tract infections trigger chronic kidney transplant rejection in man? J Urol 1998; 159:1826-1829. (Pubitemid 29190705)
30. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78:557-565. (Pubitemid 39097102)
31. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4:2029-2034.
32. Farrar CA, Keogh B, McCormack W, et al. Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J 2012; 26:799-807.
33. Leventhal JS, Schroppel B. Toll-like receptors in transplantation: sensing and reacting to injury. Kidney Int 2012; 81:826-832.
34. Naesens M, Khatri P, Li L, et al. Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int 2011; 80:1364-1376.
35. Ripoll E, Nacher V, Vidal A, et al. Cold ischaemia, innate immunity and deterioration of the glomerular filtration barrier in antibody-mediated acute rejection. Nephrol Dial Transplant 2012; 27:3296-3305.
36. Sigdel TK, Li L, Tran TQ, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012; 23:750-763.
37. Miura M, Harada H, Fukasawa Y, et al. Long-term histopathology of allografts in sensitized kidney recipients. Clin Transplant 2012; 26 (Suppl 24):32-36.
38. Yokoyama T, Konno O, Nakamura Y, et al. Interstitial fibrosis and tubular atrophy on protocol biopsies at 1 year after renal transplantation. Transplant Proc 2012; 44:607-609.
39. David-Neto E, Souza PS, Panajotopoulos N, et al. The impact of pretransplant donor-specific antibodies on graft outcome in renal transplantation: a six-year follow-up study. Clinics 2012; 67:355-361.
40. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398-1406.
41. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific HLA antibodies in pediatric late liver allografts. Liver Transplant 2012. doi: 10.1002/lt.23534. [Epub ahead of print]
42. Latinne D, Vitiello DM, Sachs DH, Sykes M. Tolerance to discordant xenografts. I. Sharing of human natural antibody determinants on miniature swine bone marrow cells and endothelial cells. Transplantation 1994; 57:238-245. (Pubitemid 24048592)
43. Goh A, Oei E, Vathsala A. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants. Transplant Proc 2012; 44:193-199.
44. Huh KH, Kim MS, Kim HJ, et al. Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches. Transplant Int 2012. doi: 10.1111/j.1432-2277.2012. 01543.x. [Epub ahead of print]
45. Segev DL. Innovative strategies in living donor kidney transplantation. Nat Rev Nephrol 2012; 8:332-338.
46. Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9:567-577.
47. Tanabe T, Ishida H, Horita S, et al. Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transplant Immunol 2011; 25:1-6.
48. Viklicky O, Zou H, Muller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69:497-502. (Pubitemid 30129579)
49. Lutz J, Huang H, Deng M, et al. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation 2007; 83:741-746. (Pubitemid 46569192)
50. Dikdan GS, Mora-Esteves C, Koneru B. Review of randomized clinical trials of donor management and organ preservation in deceased donors: opportunities and issues. Transplantation 2012; 94:425-441.
51. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302:1067-1075.
52. Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study G. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2012; 366:770-771.
53. Hamar P, Liu S, Viklicky O, et al. Cyclosporine A and azathioprine are equipotent in chronic kidney allograft rejection. Transplantation 2000; 69:1290-1295. (Pubitemid 30238713)
54. Tang SC, Chan KW, Tang CS, et al. Conversion of ciclosporin A totacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrol Dial Transplant 2006; 21:3243-3251. (Pubitemid 44567101)
55. Chen G, Chen H, Wang C, et al. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PloS One 2012; 7:e33626.
56. Albano L, Alamartine E, Toupance O, et al. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. Ann Transplant 2012; 17:58-67.
57. Szabo A, Lutz J, Schleimer K, et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57:982-991. (Pubitemid 30434788)
58. Tang L, Yi R, Yang B, et al. Valsartan inhibited HIF-1alpha pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats. Diabetes Res Clin Pract 2012; 97:125-131.
59. Liu Z, Huang XR, Chen HY, et al. Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smad-mediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy. Laboratory Invest 2012; 92:650-661.
60. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4:655-662. (Pubitemid 38523590)
61. Ahmed AK, El Nahas AM, Johnson TS. Changes in matrix metalloproteinases and their inhibitors in kidney transplant recipients. Exp Clin Transplant 2012; 10:332-343.
62. Luo L, Sun Z, Wu W, Luo G. Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy. BMC Nephrol 2012; 13:53.
63. Jiang S, Tang Q, Rong R, et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol 2012; 688:56-61.
64. Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007; 321:583-589. (Pubitemid 46624497)
65. Dharancy S, Giral M, Tetaz R, et al. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin Transplant 2012; 26:E293-E299.
66. Furuzawa-Carballeda J, Lima G, Alberu J, et al. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4alpha senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. Clin Exp Immunol 2012; 167:330-337.
67. Arora S, Tangirala B, Osadchuk L, Sureshkumar KK. Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation. Expert Opin Biol Ther 2012; 12:965-979.
68. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12:630-639.
69. Mourer JS, Hartigh J, van Zwet EW, et al. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 2012; 93:887-894.
70. Hoorn EJ, Walsh SB, McCormick JA, et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012; 25:269-275.
71. Therrien FJ, Agharazii M, Lebel M, Lariviere R. Neutralization of tumor necrosis factor-alpha reduces renal fibrosis and hypertension in rats with renal failure. Am J Nephrol 2012; 36:151-161.
72. Hultstrom M. Development of structural kidney damage in spontaneously hypertensive rats. J Hypertens 2012; 30:1087-1091.
73. Wang Y, Wang DH. Protective effect of TRPV1 against renal fibrosis via inhibition of TGF-beta/Smad signaling in DOCA-salt hypertension. Mol Med 2011; 17:1204-1212.
74. Muller V, Szabo A, Viklicky O, et al. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55:2011-2020. (Pubitemid 29197991)
75. Rusai K, Schmaderer C, Baumann M, et al. Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation. Transplantation 2012; 93:1101-1107.
76. Lutz J, Yao Y, Song E, et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005; 79:655-661. (Pubitemid 40463171)
77. Mazanowska O, Kaminska D, Krajewska M, et al. Imbalance of metalloproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury. Transplantation Proc 2011; 43:3000-3003.
78. Alfarano C, Roubeix C, Chaaya R, et al. Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemiareperfusion in cyclosporine-immunosuppressed rats. Cell Transplant 2012. doi: 10.3727/096368912X640448. [Epub ahead of print]
79. Franquesa M, Hoogduijn MJ, Bestard O, Grinyo JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012; 3:212.
80. Franquesa M, Hoogduijn MJ, Baan CC. The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. Current Opin Organ Transplant 2012; 17:355-361.
81. Franquesa M, Herrero E, Torras J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012. [Epub ahead of print]
82. Akita S, Kubota K, Kobayashi A, et al. Role of bone marrow cells in the development of pancreatic fibrosis in a rat model of pancreatitis induced by a choline-deficient/ethionine-supplemented diet. Biochem Biophys Res Commun 2012; 420:743-749.
83. Roderfeld M, Rath T, Pasupuleti S, et al. Bone marrow transplantation improves hepatic fibrosis in Abcb4-/-mice via Th1 response and matrix metalloproteinase activity. Gut 2012; 61:907-916.
84. Sugiyama N, Kohno M, Yokoyama T. Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model. Nephrol Dial Transplant 2012; 27:1351-1358.